Intravenous (IV) ketamine versus intranasal esketamine for depression- Advantage IV ketamine?

J Affect Disord. 2024 Jul 1:356:564-567. doi: 10.1016/j.jad.2024.04.088. Epub 2024 Apr 22.

Authors

Balwinder Singh¹, Simon Kung², Jennifer L Vande Voort²

Affiliations

¹ Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America. Electronic address: singh.balwinder@mayo.edu.
² Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America.

PMID: 38657763
DOI: 10.1016/j.jad.2024.04.088

No abstract available

Publication types

Letter

MeSH terms

Administration, Intranasal*
Administration, Intravenous
Antidepressive Agents / administration & dosage
Antidepressive Agents / therapeutic use
Depressive Disorder, Major / drug therapy
Humans
Ketamine* / administration & dosage
Ketamine* / therapeutic use

Substances

Ketamine
Esketamine
Antidepressive Agents